Resolution on Patent Subject Matter Eligibility
RESOLVED, that patent subject matter eligibility under 35 U.S.C. § 101 should [...]
IPO’s Request to the National Data Administration for an Extension of Time re: Comments on the “Guidelines for Data Property Rights Registration (Trial)”
IPO’s Request to the National Data Administration for an Extension [...]
Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
IPO Comments to CNIPA on Draft Amendments to the Measures for the Administration of Patent Priority Examination
IPO Comments to CNIPA on Draft Amendments to the Measures [...]
You Can’t (Always) Claim What You Didn’t Describe: U.S. and European Perspectives on Chemical Patents
You Can’t (Always) Claim What You Didn’t Describe: U.S. and [...]
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin Pharma, Inc., 24-889
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin [...]
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney Privilege
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney [...]
IPO Post-Hearing Statement to Special 301 Subcommittee
IPO Post-Hearing Statement to Special 301 SubcommitteeReadability analysis:
IPO Comments to India Department for Promotion of Industry and Internal Trade (DPIIT) on its “Concept Note: Proposed Amendment to the Designs Act, 2000″
IPO Comments to India Department for Promotion of Industry and [...]
IPO Comments to the China Standing Committee of the National People’s Congress (NPC) Regarding Draft Amendment to the Trademark Law of the People’s Republic of China
IPO Comments to the China Standing Committee of the National [...]